There is provided a production method of a thiopyranose compound represented by the following Formula (2) by reacting a compound represented by the following Formula (1) with a sulfur compound. ##STR00001##
X represents a leaving group. A represents an oxygen atom or a sulfur atom. Further, each of R.sup.1A to R.sup.4B, R.sup.1B to R.sup.4B, and R.sup.5 represents a hydrogen atom or a specific substituent.

There is provided a production method of a thiopyranose compound represented by the following Formula (2) by reacting a compound represented by the following Formula (1) with a sulfur compound. ##STR00001##
X represents a leaving group. A represents an oxygen atom or a sulfur atom. Further, each of R.sup.1A to R.sup.4B, R.sup.1B to R.sup.4B, and R.sup.5 represents a hydrogen atom or a specific substituent.

The invention relates to a multi-stage process for preparing 2,6-dialkylphenylacetic acids of the general formula (I) by reacting 2,6-dialkylbromobenzenes with (1) magnesium, (2) a formamide, (3) an acid, (4) hydrogenation of the benzaldehyde obtained, (5) activation of the benzyl alcohol obtained, (6) cyanation of the activated benzyl alcohol and (7) hydrolysis of the nitrile obtained.

Disclosed is crystalline Form A of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d.sub.3)pyridazine-3-carboxamide. Form A is a neat crystalline form. Characterization data for Form A are disclosed.

Disclosed is crystalline Form A of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d.sub.3)pyridazine-3-carboxamide. Form A is a neat crystalline form. Characterization data for Form A are disclosed.

The present application discloses a method and a compound that are useful for preparation of a compound of Formula (XI). Furthermore, the present application discloses the compound of Formula (XI) comprising a small amount of impurities.

##STR00001##

The present application discloses a method and a compound that are useful for preparation of a compound of Formula (XI). Furthermore, the present application discloses the compound of Formula (XI) comprising a small amount of impurities.

##STR00001##

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-5N-(methyl-d3)pyridazine-3-carboxamide of the formula:

##STR00001##

Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-5N-(methyl-d3)pyridazine-3-carboxamide of the formula:

##STR00001##

Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

A compound represented by formula (A) exhibits excellent balance between acid generation sensitivity and capability of providing a composition with reduced discoloration.

##STR00001##

In formula (A), R.sup.1, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, R.sup.16, R.sup.17, and n are as defined in the description. R.sup.1 is preferably an optionally substituted aliphatic hydrocarbon group having 1 to 20 carbon atoms or an optionally substituted aromatic hydrocarbon group having 6 to 20 carbon atoms.